PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
34803090-4	2021	We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC.	alectinib	48-57	ret proto-oncogene	Homo sapiens	74-77	
34803090-4	2021	We conducted an investigator-initiated trial of alectinib, which also has RET kinase-inhibitory activity, against RET-rearranged NSCLC.	alectinib	48-57	ret proto-oncogene	Homo sapiens	114-117	
34803090-5	2021	Two RET-rearranged NSCLC patients experienced severe skin toxicity with alectinib after first undergoing anti-PD-1 antibody treatment with an ICI.	alectinib	72-81	ret proto-oncogene	Homo sapiens	4-7